Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cannabinol
- Development stage
- Phase 3
- Lead developer
- InMed Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral, Inhalation, Sublingual, Topical, Transdermal
01
Overview
Cannabinol (CBN) is a mildly psychoactive phytocannabinoid found in the Cannabis sativa plant. It was the first cannabinoid to be isolated from cannabis and was discovered in 1896. CBN acts as a low-affinity partial agonist at both CB1 and CB2 receptors of the endocannabinoid system, but with much lower potency than delta-9-tetrahydrocannabinol (THC). This means that higher doses are required to produce noticeable effects, which may include mild sedation. Research on CBN is limited; early studies suggest it may affect the immune system and reduce pain, with interest in its use for sleep disorders, pain management, and appetite stimulation[1][3].
- Other names
- cannabinolCBN
02
Targets
CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on cannabinol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cannabinol.